Ann: 3 Articles on RYONCIL GvHD Trial Results Published in BBMT, page-8

Key points:

• Biology of Blood and Marrow Transplantation, the official publication of the American Society
for Transplantation and Cellular Therapy, publishes three peer-reviewed articles detailing
results from three separate trials of remestemcel-L in children and adults with acute graft
versus host disease

• Publications highlight consistent benefits seen across all three trials in patients with greatest
levels of inflammation and the most severe grades of the disease

• Trial results underpin Mesoblast’s Biologics License Application to seek approval of its product
candidate RYONCIL™ (remestemcel-L) for pediatric steroid-refractory acute graft versus host
disease (GVHD), which has been accepted for priority review by the United States Food and
Drug Administration (FDA)

• These outcomes also provide the rationale for use of remestemcel-L in other conditions
associated with severe inflammation and cytokine release, including COVID-19 infection